Fig. 3.

Individual level data for HMFSE and RULM from Day 1 to Day 302 in Part A with x-axis showing age of participants. A: HFMSE total score. B: RULM total score. Most participants in Part A showed improvement or stabilization in motor function after treatment with nusinersen 28 mg. *Participant 2 reported a fall and fractured femur as treatment-emergent adverse events on Day 287, prior to the end of study visit; this participant had a 7-point decrease in HMFSE score from baseline to end of study, likely due to these adverse events. HFMSE, Hammersmith Functional Motor Scale –Expanded. RULM, Revised Upper Limb Module.